Moclobemide

證據等級: L5

預測適應症: 2 個

One-Sentence Summary

Moclobemide is a reversible, selective monoamine oxidase-A inhibitor (RIMA), approved in multiple international markets for depression and social anxiety disorder. The TxGNN model predicts it may be effective for Agoraphobia, with 0 clinical trials and 12 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Social Anxiety Disorder / Depression (European approved indications; no Canadian registration on file)
Predicted New Indication	Agoraphobia
TxGNN Prediction Score	99.43%
Evidence Level	L3
Canada Market Status	Not Marketed
Number of DINs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on published literature, Moclobemide belongs to the RIMA (Reversible Inhibitor of Monoamine Oxidase-A) class. It acts by selectively and reversibly inhibiting MAO-A, thereby reducing the degradation of serotonin, norepinephrine, and dopamine. This upregulates monoaminergic tone in anxiety-relevant brain regions — including the amygdala, hippocampus, and prefrontal cortex — producing anxiolytic and antidepressant effects. Moclobemide’s approval in Europe for social anxiety disorder directly establishes its utility in modulating the anxiety neural circuit.

Agoraphobia and panic disorder share a deeply overlapping clinical and neurobiological profile. Under DSM-III/IV, the combined diagnosis “panic disorder with agoraphobia” was standard practice, and most published trials enrolled patients under this combined label. Critically, both RCTs identified in this evidence pack (PMID 10448444; PMID 10361962) specifically studied patients with panic disorder with agoraphobia — meaning the existing clinical evidence directly addresses the comorbid population rather than panic disorder alone.

The same cortico-limbic anxiety circuits implicated in agoraphobia are targeted by moclobemide’s RIMA mechanism, which has already demonstrated efficacy across multiple anxiety phenotypes: social anxiety disorder (European approval), panic disorder (RCT evidence), and mixed anxiety-depression. Reviews spanning from 1990 to 2020 consistently confirm the MAOI/RIMA class as active across the anxiety disorder spectrum. This mechanistic and phenotypic overlap strongly supports the biological plausibility of the TxGNN prediction.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
10448444	1999	RCT	Br J Psychiatry	Placebo-controlled RCT directly comparing moclobemide, CBT, and their combination in panic disorder with agoraphobia; establishes moclobemide as an efficacious pharmacological option in this population
10361962	1999	RCT	Eur Arch Psychiatry Clin Neurosci	Multicenter double-blind RCT (n=135): moclobemide 450 mg/day vs clomipramine 150 mg/day in DSM-III-R panic disorder with/without agoraphobia; comparable efficacy with favourable tolerability
32002937	2020	Review	Adv Exp Med Biol	Comprehensive evidence-based review of pharmacotherapy for anxiety disorders (panic disorder/agoraphobia, GAD, SAD) grounded in meta-analyses and systematic reviews of randomised controlled studies
28867934	2017	Review	Dialogues Clin Neurosci	Guideline-based review of anxiety disorder management including panic disorder/agoraphobia; addresses treatment gaps in primary care and catalogues pharmacological options
7717094	1995	Review	Acta Psychiatr Scand Suppl	Meta-analysis confirms moclobemide’s antidepressant and anxiolytic activity vs multiple comparators (TCAs, SSRIs, other MAOIs) across depressive and anxiety disorders
2248064	1990	Review	Acta Psychiatr Scand Suppl	MAOIs demonstrated effective in controlled studies of panic disorder with agoraphobia, social phobia, PTSD, and mixed anxiety-depression; reviews clinical evidence for irreversible and reversible agents
8313401	1993	Clinical Study	Clin Neuropharmacol	Randomised double-blind 8-week trial in panic disorder evaluating RIMA class (brofaromine); confirms better tolerability vs clomipramine without dietary restrictions — contextualises moclobemide class advantages
16850261	2006	Neuroimaging Study	Metab Brain Dis	SPECT neuroimaging compares citalopram and moclobemide effects on resting brain perfusion in social anxiety disorder; supports shared cortico-limbic mechanism across anxiety phenotypes
12006898	2002	Clinical Analysis	J Clin Psychopharmacol	Pharmacodynamic modelling of moclobemide treatment response in panic disorder; regression-slope analysis examines baseline severity–treatment interaction, informing patient selection
7954487	1994	Open-label Study	Clin Neuropharmacol	12-week open-label pilot (n=35): moclobemide 300–600 mg/day in social phobia; consistent improvement in both fear and avoidance components with good tolerability

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two RCTs from 1999 directly tested moclobemide in patients with panic disorder with agoraphobia, and the RIMA mechanism is already approved for social anxiety disorder in Europe — together these provide both clinical and mechanistic grounding for this repurposing direction. However, the evidence base is dated, no trials are currently registered for standalone agoraphobia, and safety documentation is unavailable in the current data pack, preventing a full risk-benefit evaluation.

To proceed, the following is needed:

Full prescribing information (package insert / SmPC) to complete the safety, contraindication, and drug interaction assessment
MOA documentation from DrugBank to formalise the mechanistic rationale
Verification of current Canadian regulatory status via Health Canada’s Drug Product Database (DPD)
A systematic review or meta-analysis specifically targeting moclobemide in agoraphobia under DSM-5 criteria (standalone diagnosis), to address the gap between the older combined panic/agoraphobia trials and current diagnostic standards
Comparative effectiveness data against current first-line therapies (SSRIs, SNRIs, CBT) to establish the clinical positioning of moclobemide in an agoraphobia-specific treatment pathway
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.